Fig. 2: Risk factors and survival for POD24. | Blood Cancer Journal

Fig. 2: Risk factors and survival for POD24.

From: Progression of disease within 24 months (POD24) in follicular lymphoma in the rituximab era: incidence, clinicopathological risk factors, and outcome in a population-based Danish cohort

Fig. 2

A Hazard ratios and forest plots comparing clinicopathological factors between POD24-neg and POD24-pos patients. Multivariate analysis was performed with imputated missing values under the assumption that data were missing at random. *Adjusted for risk factors not included in the FLIPI score. B Overall survival from a risk-defining event was defined as survival from time of a progressive event for POD24-pos patients and 24 months after treatment initiation for POD24-neg patients. C Progression-free survival in the POD24-neg patient group. β2m β2-microglobulin, BM bone marrow, CI confidence interval, FL follicular lymphoma, FLIPI follicular lymphoma international prognostic index, HR hazard ratio, LDH lactate dehydrogenase, NA not applicable, NS not significant, OS overall survival, PFS progression-free survival, POD24 progression of disease within 24 months from diagnosis, R rituximab.

Back to article page